Clinical trials: SARCOIDOSIS
Pulmonary Sarcoidosis
An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Open-label Study to Evaluate the Long-term Safety and Durability of Effect of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extra-pulmonary Involvement
- Trial name
- NCT06169397
- Testing
- XTMAB-16
- Where
- 11 sites in United States, Czechia and 2 more
- Volunteers
- 31 people
- Sponsor
- Xentria, Inc.
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung
A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
This study will evaluate whether participants with serious lung diseases such as idiopathic pulmonary fibrosis, sarcoidosis, and pulmonary hypertension who use the FORTISKAP™ smart medication cap - a bottle-top device that tracks…
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
- Trial name
- NCT07613216
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cosmos Rx, Inc
Neoplasms
Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses
Although Neopharm has terminated its sponsorship of this study, it is continuing under the sponsorship of the NCI. Please contact Raffit Hassan, MD at 301-451-8742 for more information.
- Trial name
- NCT00024687
- Testing
- SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin
- Where
- United States
- Sponsor
- INSYS Therapeutics Inc
Pulmonary Sarcoidosis
A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)
Researchers are looking for new ways to treat active pulmonary sarcoidosis (PS). This trial will help researchers learn if a trial medicine called tulisokibart can treat symptoms of active PS.
- Trial name
- NCT07867938
- Testing
- Tulisokibart, Background prednisone therapy
- Volunteers
- 158 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Sarcoidosis
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects…
- Trial name
- NCT06205121
- Testing
- OATD-01
- Where
- 28 sites in United States, Denmark and 6 more
- Volunteers
- 96 people
- Sponsor
- Molecure S.A.
Lung Disease, Chronic Obstructive, Lung Disease, Interstitial
Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)
This is a study that seeks to characterize data obtained from patients with a variety of lung diseases using ultrasound signals obtained from the lung tissue.
- Conditions
- Lung Disease, Chronic Obstructive, Lung Disease, Interstitial, Asthma, Sarcoidosis
- Trial name
- NCT01361139
- Where
- 2 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Echosense Ltd.
Pulmonary Sarcoidosis
Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis
This is a multicenter, randomized, double-blind, placebo-controlled, study comparing the efficacy and safety of intravenous (IV) efzofitimod 3 mg/kg and 5 mg/kg versus placebo after 48 weeks of treatment.
- Trial name
- NCT05415137
- Testing
- Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg
- Where
- 91 sites in United States, Brazil and 7 more
- Volunteers
- 268 people
- Sponsor
- aTyr Pharma, Inc.
Sarcoidosis
A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis
This study tests the safety and effectiveness of ustekinumab or golimumab compared to placebo (placebo looks like the drugs being studied, but has no active ingredients).
- Trial name
- NCT00955279
- Testing
- Golimumab, Ustekinumab
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 173 people
- Sponsor
- Centocor, Inc.
Stage 2 Pulmonary Sarcoidosis, Stage 3 Pulmonary Sarcoidosis
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following…
- Trial name
- NCT01440192
- Testing
- PDA001 (cenplacel-L)
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Celularity Incorporated
Pulmonary Sarcoidosis
An Efficacy Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
A study of XTMAB-16 in patients with pulmonary sarcoidosis
- Trial name
- NCT07680166
- Testing
- XTMAB-16
- Volunteers
- 182 people
- Sponsor
- Xentria, Inc.
Progressive Pulmonary Fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
- Trial name
- NCT06025578
- Testing
- BMS-986278
- Where
- 459 sites in United States, Argentina and 33 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Lung Diseases, Interstitial
Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)
This study aims to characterize the epidemiology of interstitial lung diseases (ILD) associated to connective tissue disease (CTD) in Mexico, and to study its correlation with the different comorbidities and treatments used, as…
- Trial name
- NCT05819385
- Where
- Mexico
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Sarcoidosis
A Phase 2 Study With CC-220 in Skin Sarcoidosis
This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of oral CC-220 in adult subjects with chronic cutaneous sarcoidosis.
- Trial name
- NCT02192489
- Testing
- CC-220 0.3 mg Daily, CC-220 0.6mg Daily
- Sponsor
- Celgene
Pulmonary Sarcoidosis
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations
Study of Multiple-Ascending-Dose Study of XTMAB-16 in Patients with Pulmonary Sarcoidosis with or Without Extrapulmonary Manifestations
- Trial name
- NCT05890729
- Where
- 33 sites in United States, Czechia and 4 more
- Volunteers
- 32 people
- Sponsor
- Xentria, Inc.
Cutaneous Sarcoidosis
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
- Trial name
- BEACON (NCT06978725)
- Testing
- Oral Brepocitinib
- Where
- 44 sites in United States, Australia and 1 more
- Volunteers
- 168 people
- Sponsor
- Priovant Therapeutics, Inc.
Sarcoidosis, Pulmonary
Acthar Gel in Participants With Pulmonary Sarcoidosis
The purpose of this study is to find out if Acthar Gel is safe and effective to treat pulmonary sarcoidosis. Participants will be randomly assigned (like flipping a coin) to receive a shot under their skin of Acthar Gel or a…
- Trial name
- PULSAR (NCT03320070)
- Testing
- Acthar Gel
- Where
- 29 sites in United States
- Volunteers
- 55 people
- Sponsor
- Mallinckrodt
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Sarcoidosis, Pulmonary
A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis
This is a multicenter, single-arm, unblinded/open-label study of the effect size of HRCT endpoints in response to glucocorticoid induction therapy in subjects with a diagnosis of pulmonary sarcoidosis who have not received…
- Trial name
- NCT03324503
- Testing
- Glucocorticoid (prednisone or prednisolone)
- Where
- 20 sites in United States, Netherlands and 1 more
- Volunteers
- 8 people
- Sponsor
- Celgene
Neuropathy of Sarcoidosis
Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
The purpose of this study is to determine whether ARA 290, a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis.
- Trial name
- NCT02039687
- Testing
- ARA 290
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 64 people
- Sponsor
- Araim Pharmaceuticals, Inc.
Sarcoidosis Associated Pulmonary Hypertension
LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 (Inhaled Sirolimus) in Adults with Sarcoidosis Associated Pulmonary Hypertension (SAPH)
- Trial name
- NCT07886554
- Testing
- LAM-001
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- IRulya Therapeutics Inc.